Addex Trading Update: Completes 2018 with Strong Cash Position
January 07, 2019 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 7th January 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has completed...
Addex Van Leeuwenhoeck Equity Research Report Highlights Deep Pipeline Well Funded through Pivotal Registration Study and Increases Price Target to CHF 14
November 22, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 22 November 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that the independent...
Addex to Present at the Biotech and Money Inv€$tival Showcase and Participate in the Jefferies London Healthcare Conference
November 12, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 12th November 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer,...
Addex Selective mGlu2 PAM ADX71149 Included in Review Highlighting Promising Investigative Drugs for Epilepsy (Review Published in Epilepsia Journal)
October 22, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 2 October 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its selective...
Addex to Present at the Sachs 18th Annual Biotech in Europe Forum
October 02, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 2 October 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will...
Addex Reports 2018 Half-Year Financial Results and Provides Corporate Update
September 28, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 28 September 2018 – Addex Therapeutics (SIX: ADXN), a company pioneering allosteric modulation-based drug discovery and development, today reported its half-year financial results...
ADDEX THERAPEUTICS RECOGNISED IN FINAL SHORTLIST FOR DEAL OF THE YEAR AT LIFESTARS AWARDS LIFE SCIENCE AWARDS FOR PARTNERSHIP WITH INDIVIOR
September 25, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland and London, UK, 25 September 2018 – Addex Therapeutics (SIX: ADXN), a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric...
Addex to Present at the Investora Zurich Conference on 27 September
September 25, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 25 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer,...
Addex ADX10061 Receives £1.2 million Funding for Manufacture and Investigator Led Clinical Studies as part of the Tools for Human Drug and Brain Research (THuNDR2) Initiative from the Wellcome Trust
September 20, 2018 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 20 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that it has joined the...
Addex’s Selective mGlu2 PAM ADX71149 Shows Promise in Treating Severe Panic Disorders and PTSD
September 04, 2018 01:00 ET
|
Addex Therapeutics
Preclinical and Adhoc Clinical Data Published in Molecular Psychiatry Geneva, Switzerland, 4 September 2018 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric...